This article is more than 5 years old. Information may no longer be current.

NicOx reports €353,000 first-half net loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NicOx recorded €7.5 million in revenue for the first 6 months of 2012, resulting in a net loss of €353,000, according to a press release.

The company lost €7.8 million during the same period last year.    

The revenue comes as a result of a one-time €10 million milestone payment from Bausch + Lomb in April following the company’s decision to continue development of BOL-303259-X, a novel nitric oxide-donating prostaglandin F2 alpha analogue licensed by NicOx to Bausch + Lomb, the release said.

In the first half of this year, NicOx also entered into a licensing agreement with Rapid Pathogen Screening for AdenoPlus, an in-office diagnostic test for adenoviral conjunctivitis. The product is authorized for marketing in the United States and Europe and is expected to be launched by the end of the year, the release said.

NicOx’s research and development expenses were €3.2 million in the first half of 2012, compared to €5.3 million for the same period of 2011, the release said. Administrative expenses fell to €1.9 million from €2.6 million, while selling expenses increased to €3 million from €1 million.